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Abstract 4887 
Introduction: Chronic active Epstein-Barr virus infection (CAEBV) has been implicated in 
several diseases including hemophagocytic lymphohistiocytosis (EBV-HLH) and lymphomas 
including Angioimmunoblastic T cell lymphoma. The exact mechanism by which EBV infection 
causes these complications is currently not well understood. EBV-HLH is a syndrome in which 
T-cells, NK cells and macrophages are aberrantly activated. Cytokine storms play a major role in 
cellular damage and organ dysfunction. In the event that the body is unable to clear the EBV 
viremia, dysregulated T, NK cells and macrophages continue to release cytokines leading to the 
accumulation of lymphohistiocytic infiltrates into organs and organ damage. Cytokine storms 
can lead to death from multi-organ failure. During a cytokine storm, levels of several cytokines 
are elevated including TNF-a, IFN-g, sCD25, IL-12, IL-1, IL-10 and IL-18.
1–3
 Current lines of 
therapy of EBV-HLH include steroids, etoposide, cyclosporine, ATG and hematopoietic stem 
cell transplantation. We report successfully controlling frequent cytokine storms in a patient with 
EBV induced angioimmunoblastic lymphoma and HLH with weekly infliximab after failure to 
do so with chemotherapy (CHOP-E; cyclophosphamide, daunorubicin, vincristine, prednisone, 
etoposide), rituximab and bortezomib. 
Case: This is a 35 year old African American male with a long history of adenopathy who 
presented with autoimmune hemolytic anemia, autoimmune thrombocytopenia (ITP), 
neutropenia with fever and hypotension. Work up revealed persistent EBV viremia and the 
lymph node biopsy revealed Angioimmunoblastic T cell lymphoma. High dose dexamethasone 
and Intravenous immunoglobulins (IVIG) failed to control his hemolysis and ITP. Rituximab and 
bortezomib successfully controlled his autoimmune hemolysis and thrombocytopenia. However, 
cytokine storm episodes, characterized by high fevers, hypotension and respiratory distress, 
continued every 1–2 weeks requiring ICU admissions. Chemotherapy (CHOP-E), for his 
underlying lymphoma, followed by etoposide/steroids (HLH-94 protocol) were also ineffective 
at controlling his cytokine storms. Considering that he had high levels of TNF-a, infliximab was 
started in an attempt to control dysregulated macrophages and T-cells, and was able to 
successfully prevent the cytokine storms. High levels of IL-6, soluble IL-2 receptor and TNF-a 
were all detected during cytokine storm episodes. The patient is currently getting prepared for an 
allogeneic stem cell transplant. 
Discussion: We report successful control of EBV-HLH related cytokine storms, guided by TNF-
a levels, with weekly infliximab (Fig 1). Hypercytokinemia is believed to result from 
dysregulated T cells, NK cells and macrophages as a result of failure to control the EBV viremia. 
In this case a TNF-a inhibitor (infliximab) was used to control dysregulated macrophages, T and 
NK cells and block further propagation of inflammatory cytokines. Initially infliximab was 
initiated on a once every 2 week schedule, however, this failed to prevent cytokine storms with 
high TNF-a levels. However, weekly dosing of infliximab successfully prevented cytokine 
storms and controlled his TNF-a levels (Fig 1). Moreover, an attempt to taper off the weekly 
infliximab and etoposide resulted in relapse of his symptoms and a sharp rise in ferritin levels, a 
marker for HLH activity (Fig 2). This suggests that infliximab might be an effective therapy in 
preventing cytokine storms related to EBV-HLH and further studies are warranted. 
 
 
 
